Sickle Cell Disease Genomics Network of Africa
Nearly 2% of births in sub-Saharan Africa are affected with sickle cell disease (SCD). Bacteria-related deaths in SCD have reduced dramatically in children in the last 30 years in the West, and it is anticipated that a similar drop will occur in Africa once prevention and prompt management of infections becomes widely implemented on the continent. During this same period, the death rate among adolescents and adults with SCD has not improved largely because we cannot predict, prevent and effectively
manage the end-stage organ damage typical of this disease. The SickleGenAfrica Network is made up of African scientists and international collaborators who are going to study 7,000 children and adults with SCD in Africa to identify genetic markers associated with the development of organ damage, with a special emphasis on the body’s defence against molecules released from damaged red blood cells that cause tissue injury. The long-term goal of the network is to develop strategies to predict, prevent and treat organ damage in SCD.
To align the survival of individuals who have sickle cell disease in Africa with national
To develop prognostic biomarkers of organ damage through the discovery of key
genetic modifying factors and cognate mechanisms, and build capacity and career
pipelines in Africa to support patient-centred research to advance the development of
innovative therapy for SCD.
Administration & Examination Hall Building.
School of Biomedical and Allied Health Sciences.
University of Ghana,
Korle Bu, Accra, Ghana
+233 303 970949
SickleGenAfrica is funded by NIH Common Fund Award / NHLBI Grant Number U54HL141011
The SickleGenAfrica website content is solely the responsiblity of the authors and does not necessarily represent the official views of the National Institutes of Health.
© 2017 SickleGenAfrica